BioSpace News Archive

RVL Pharmaceuticals plc today announced that the Company will release its fourth quarter and full year 2022 financial results and provide a commercial update on Monday, March 20, 2023, before U.S. financial markets open.

iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announced that the first patients have been implanted in its STAR-VI international trial evaluating the safety and efficacy of MINIject® in conjunction with cataract surgery in patients with primary open-angle glaucoma.

Gritstone bio, Inc. today announced multiple presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023 in Orlando, Florida.

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and provided a corporate update for the fourth quarter and full year 2022, as well as the outlook for 2023.

Doctors in the U.S. can now access a novel NAD+ blood diagnostic for their patients.

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the publication of an abstract that has been accepted for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 – 19, 2023.

iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter and full year ended December 31, 2022.

Aravive, Inc. today reported fourth quarter and full year ended December 31, 2022 financial results and provided corporate updates.

Kamada Ltd. today announced financial results for the 12 and three months ended December 31, 2022.

Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities.